Page last updated: 2024-11-13
hectorite
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
hectorite: clay constituent of bentonite; approx. formula: Na0.67(Mg,Li)6Si8020(OH,F)4 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 72941499 |
MeSH ID | M0061374 |
Synonyms (23)
Synonym |
---|
hectorite ((mg2.67li0.33)si4na0.33[f0.5-1(oh)0-0.5]2o10) |
einecs 235-340-0 |
hectorite (clay mineral) |
hectorite ((mg2.67li0.33)si4na0.33(f0.5-1(oh)0-0.5)2o10) |
12173-47-6 |
08x4ki73ez , |
hectorite |
unii-08x4ki73ez |
Q3129310 |
lithium;magnesium;sodium;1,3,5,7-tetraoxido-2,4,6,8,9,10-hexaoxa-1,3,5,7-tetrasilatricyclo[5.1.1.13,5]decane;dihydroxide |
hectorite [inci] |
accofloc hcx |
optigel sh |
hectabrite aw |
hectabrite dp |
hectabrite 200 |
bentone hc |
sumecton he |
bentone ct |
astratone 40 |
a montmorillonite mineral, a principal constituent of bentonite clay |
hectabrite lt |
hectorite [mi] |
Research Excerpts
Overview
Hectorite is a clay belonging to the smectite group. It has attracted attention for applications in biology, tissue engineering and as drug carrier and delivery system.
Excerpt | Reference | Relevance |
---|---|---|
"Hectorite (Ht) is a clay belonging to the smectite group which has attracted attention for applications in biology, tissue engineering and as drug carrier and delivery system." | ( Exploring the cellular uptake of hectorite clay mineral and its drug carrier capabilities. de Melo Barbosa, R; Emili, C; Liotta, LF; Massaro, M; Notarbartolo, M; Poma, P; Raymo, FM; Riela, S; Sànchez-Espejo, R; Vago, R; Viseras-Iborra, C, 2022) | 1.72 |
Effects
Hectorite clay has been modified using two cationic surfactants, cetyldimethylbenzylammonium chloride and cetylpyridinium chloride.
Excerpt | Reference | Relevance |
---|---|---|
"A Hectorite sample (H) has been chemically modified with N-propyldiethylenetrimethoxysilane and bis[3-(triethoxysilyl)propyl]tetrasulfide. " | ( Modification of hectorite by organofunctionalization for use in removing U(VI) from aqueous media: thermodynamic approach. Airoldi, C; Guerra, DL; Viana, RR, 2010) | 1.43 |
"Hectorite clay has been modified using two cationic surfactants, cetyldimethylbenzylammonium chloride and cetylpyridinium chloride." | ( Equilibrium studies for the adsorption of acid dye onto modified hectorite. Baskaralingam, P; Pulikesi, M; Ramamurthi, V; Sivanesan, S, 2006) | 1.29 |
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" The Panel reviewed available animal and human data and concluded that these ammonium hectorite compounds were safe as cosmetic ingredients in the practices of use and concentration as given in this safety assessment." | ( Safety assessment of ammonium hectorites as used in cosmetics. Andersen, FA; Becker, LC; Belsito, DV; Bergfeld, WF; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW, ) | 0.64 |
" Therefore, the aim of this study was to evaluate and compare the potential toxic effects of a wide range of commercially available SLS and NLS of varying physicochemical properties (lithium (Li) or fluoride (F) content and size)." | ( An in vitro assessment of the toxicity of two-dimensional synthetic and natural layered silicates. Brown, DM; Maciaszek, K; Stone, V, 2022) | 0.72 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"Electron paramagnetic resonance spectroscopy is used to monitor the bioavailability of a nitroxide spin probe, 4-hydroxy-Tempo or Tempol, in Ca-hectorite suspensions and pastes, to bacteria capable of degrading this probe co-metabolically." | ( EPR monitoring of the bioavailability of an organic xenobiotic (4-hydroxy-TEMPO) in model clay suspensions and pastes. Baveye, P; Berthelin, J; Bladon, R; Dumestre, A; Spagnuolo, M, 2006) | 0.53 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (39)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (5.13) | 18.7374 |
1990's | 4 (10.26) | 18.2507 |
2000's | 11 (28.21) | 29.6817 |
2010's | 17 (43.59) | 24.3611 |
2020's | 5 (12.82) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 53.06
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (53.06) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 41 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |